Summit Therapeutics Inc.SMMT
NasdaqGM•Healthcare•Biotechnology
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics Inc. (SMMT) reported trailing twelve months revenue of $0 as of March 2026, a NaN% decline year-over-year. Quarterly revenue reached $0, reflecting a contraction in sales.
Summit Therapeutics Inc. reported a TTM net loss of $1.21B, with quarterly EBITDA of $-195.21M. The operating margin contracted from -6685100000.0% to -19521200000.0%, suggesting rising cost pressures or pricing headwinds.
The spread between operating margin (-19521200000.0%) and net margin (-18942400000.0%) indicates tight cost control with minimal non-operating drag. Net margin has narrowed from -6291300000.0% a year ago, reflecting increased costs or interest expense.
SMMT trades at a P/S of N/A. The price-to-book ratio of 24.1x indicates a significant premium over book value.
The company reported negative free cash flow of $-122.54M, indicating cash consumption over the period. The balance sheet shows $647.86M in total assets with no in long-term debt against $545.93M in stockholders equity. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are under pressure, averaging -18415562500.0%. The business may lack pricing power or face rising costs.'
ROE is low or negative, suggesting limited competitive advantage or capital allocation challenges.
Only 0 of the last 8 quarters had positive FCF — the business may require external capital to sustain operations.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 21 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
Limited debt-to-equity data available.
Revenue is stable or growing over recent quarters — demand appears durable.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares outstanding increased 9.5% — significant dilution, likely from stock compensation or capital raises.